Third Harmonic Bio (THRD) Stock Price, News & Analysis

Company Overview

TF Financial Corporation is a savings and loan holding company. The Company's direct and indirect subsidiaries include Third Federal Bank (the Bank), Teragon Financial Corporation, Penns Trail Development Corporation and Third Delaware Corporation. The Bank is a community oriented Pennsylvania stock savings bank offering a variety of financial services to meet the needs of the communities it serves. As of December 31, 2011 the Bank operated fourteen branch offices in Bucks and Philadelphia Counties, Pennsylvania and in Mercer County, New Jersey. During the year ended December 31, 2011, the Company's subsidiary, TF Investments Corporation merged into TF Financial Corporation. In July 2013, the Company acquired Roebling Financial Corp, Inc. (Roebling) and its wholly-owned subsidiary, Roebling Bank.

Key Stats

• Today's Range: $5.38 to $5.38
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 247,013 shs
• Market Capitalization: $242.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

Third Harmonic Bio Stock Analysis - MarketRank™

Third Harmonic Bio scored higher than 6% of companies evaluated by MarketBeat, and ranked 924th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Third Harmonic Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Third Harmonic Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Third Harmonic Bio are expected to decrease in the coming year, from ($1.08) to ($1.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Third Harmonic Bio is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Third Harmonic Bio is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Third Harmonic Bio has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.37% of the float of Third Harmonic Bio has been sold short.

Short Interest Ratio / Days to Cover

Third Harmonic Bio has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Third Harmonic Bio has recently decreased by 4.05%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Third Harmonic Bio does not currently pay a dividend.

Dividend Growth

Third Harmonic Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.37% of the float of Third Harmonic Bio has been sold short.

Short Interest Ratio / Days to Cover

Third Harmonic Bio has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Third Harmonic Bio has recently decreased by 4.05%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Third Harmonic Bio this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Third Harmonic Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.80% of the stock of Third Harmonic Bio is held by insiders.

Percentage Held by Institutions

93.95% of the stock of Third Harmonic Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

THRD Stock Analysis - Frequently Asked Questions

How were Third Harmonic Bio's earnings last quarter?

Third Harmonic Bio, Inc. (NASDAQ:THRD) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.09.

When did Third Harmonic Bio IPO?

Third Harmonic Bio (THRD) raised $185 million in an initial public offering on Thursday, September 15th 2022. The company issued 10,900,000 shares at a price of $16.00-$18.00 per share.

Who are Third Harmonic Bio's major shareholders?

Top institutional investors of Third Harmonic Bio include TCG Crossover Management LLC (4.24%), Geode Capital Management LLC (1.28%), DLD Asset Management LP (1.12%) and OMERS ADMINISTRATION Corp (0.95%). Insiders that own company stock include Bvf Partners L P/Il, Natalie C Holles, Julie Person, Jennifer Dittman and Edward R Conner.
View institutional ownership trends.

What other stocks do shareholders of Third Harmonic Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Third Harmonic Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), ServiceNow (NOW) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:THRD
• CIK: 921051
• Web: www.thirdfedbank.com
• Phone: +1-215-5794000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Third Harmonic Bio: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: -7.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -19.27%
• Return on Assets: -18.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 54.10
• Quick Ratio: 54.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.33 per share
• Price / Book: 0.85

Miscellaneous

• Outstanding Shares: 45,130,000
• Free Float: 41,608,000
• Market Cap: $242.80 million
• Optionable: Optionable
• Beta: 2.12